未知发病时间卒中无需高级影像再灌注 (UTOPIA)
基于非对比CT选择对发病时间不明的急性缺血性卒中患者静脉注射替奈普酶:一项多中心、前瞻性、随机、开放标签、盲法终点试验
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.
研究概览
地位
详细说明
UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.
Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Dong Pan, MD, PhD
- 电话号码:86-156 2648 3251
- 邮箱:dongpan012@hotmail.com
学习地点
-
-
Fujian
-
Xiamen、Fujian、中国、361004
- 尚未招聘
- Zhongshan Hospital of Xiamen University
-
接触:
- Xingyu Chen
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510620
- 尚未招聘
- Guangzhou Twelfth People's Hospital
-
接触:
- Jianwu Dai
-
-
Guangxi
-
Baise City、Guangxi、中国、533000
- 尚未招聘
- Baise People's Hospital
-
接触:
- Dengxing Li
-
Chongzuo、Guangxi、中国、532200
- 招聘中
- The People's Hospital of Chongzuo
-
接触:
- Jianyi Huang
-
Guigang、Guangxi、中国、537121
- 尚未招聘
- People's Hospital of Qintang District, Guigang City
-
接触:
- Jixin Lu
-
Guigang、Guangxi、中国、537200
- 尚未招聘
- Guiping People's Hospital
-
接触:
- Peiquan Yang
-
Laibin、Guangxi、中国、545900
- 尚未招聘
- Wuxuan County People's Hospital
-
接触:
- Yu Huang
-
Liuzhou、Guangxi、中国、545007
- 尚未招聘
- Liuzhou Workers' Hospital
-
接触:
- Liya Pan
-
Nanning、Guangxi、中国、530021
- 尚未招聘
- The First Affiliated Hospital of Guangxi Medical University
-
接触:
- Dong Pan, MD, PhD
- 电话号码:86-156 2648 3251
- 邮箱:dongpan012@hotmail.com
-
首席研究员:
- Yuan Wu, MD, PhD
-
Nanning、Guangxi、中国、530200
- 尚未招聘
- Nanning Yongning District People's Hospital
-
接触:
- Wuqiao Liang
-
接触:
- Qihai Zhou
-
Nanning、Guangxi、中国、530219
- 尚未招聘
- Guangxi Medical University Kaiyuan Langdong Hospital
-
接触:
- Kai Chen
-
Nanning、Guangxi、中国、530409
- 尚未招聘
- No.9 People's Hospital of Nanning
-
接触:
- Jun Qu
-
Qinzhou、Guangxi、中国、535000
- 尚未招聘
- The Second People's Hospital of Qinzhou
-
接触:
- Caixia Xuan
-
-
Shaanxi
-
Yulin、Shaanxi、中国、718100
- 尚未招聘
- Mizhi County Hospital
-
接触:
- Tao Zhang
-
Yulin、Shaanxi、中国、718600
- 尚未招聘
- Dingbian County People's Hospital
-
接触:
- Gaiyan Qu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years old.
- Clinical diagnosis of acute ischemic stroke.
- Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
- Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
- National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
- Planned endovascular treatment.
- Rapid neurological improvement with NIHSS <6 at randomization.
- Allergy to tenecteplase.
- Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
- Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
- Severe traumatic brain injury or other major trauma in the past 3 months.
- Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
- Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
- Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
- Active internal bleeding.
- Aortic dissection.
- Infective endocarditis.
- Platelet count <100×10^9/L.
- Women who are pregnant or breastfeeding.
- Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
- Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
- Life expectancy <3 months.
- Participating in other trials.
- Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Control group
Standard Medical Treatment |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. |
|
实验性的:Tenecteplase group
Intravenous tenecteplase thrombolysis |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Excellent outcome
大体时间:90 (±14) days
|
The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days |
90 (±14) days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Level of disability
大体时间:90 (±14) days
|
Ordinal shift analysis of the mRS with 5-6 merged at 90 days. |
90 (±14) days
|
|
Functional independence
大体时间:90 (±14) days
|
The proportion of mRS score of 0-2 at 90 days. |
90 (±14) days
|
|
Early neurological improvement
大体时间:24 (±12) hours
|
The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours. |
24 (±12) hours
|
|
Change in stroke severity
大体时间:7 (±1) days or at discharge
|
The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first) |
7 (±1) days or at discharge
|
|
Quality of life measured by EQ-5D-5L
大体时间:90 (±14) days
|
EQ-5D-5L scale score at 90 days. |
90 (±14) days
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Symptomatic intracranial hemorrhage
大体时间:24 (±12) hours
|
Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria) |
24 (±12) hours
|
|
Any intracranial hemorrhage
大体时间:24 (±12) hours
|
Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification) |
24 (±12) hours
|
|
Extracranial bleeding
大体时间:24 (±12) hours
|
Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization |
24 (±12) hours
|
|
Mortality
大体时间:90 days
|
All cause death within 90 days. |
90 days
|
合作者和调查者
调查人员
- 首席研究员:Yuan Wu, MD, PhD、First Affiliated Hospital of Guangxi Medical University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2026-K0237
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.